Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | Director | October 06, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RECURSION PHARMACEUTICALS, INC.
Report date October 06, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 6,108,287 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Sale · Disposed 50,000 · Balance 6,108,287 F1: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025. F2: This transaction was executed in multiple trades at prices ranging from $4.80 to $5.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $4.80 to $5.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2021 Filed Apr 19, 2021 23:21 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-027389 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765,304 F1 · security: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. F2 · shares: The shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of common stock of the Issuer, with all such shares being received on the earlier of April 16, 2022 or the Issuer's first annual meeting of stockholders. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 23:21 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-21-027389 · doc4.xml · derivative · entry 2 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-04-14 F3 · derivative.exercise_date: The option becomes exercisable as to all of the shares subject to the option on the earlier of April 15, 2022 and the Issuer's first annual stockholder meeting. F1 · derivative.underlying: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.